ReviewMicrobial cell factories2021
Rhamnolipid the Glycolipid Biosurfactant: Emerging trends and promising strategies in the field of biotechnology and biomedicine.
Review in Microbial cell factories, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 262 citations in OpenAlex.
- Natural products shape microbial ecology and disease in the cystic fibrosis airway.Natural product reports · 2026Review
- Biosurfactant-Based Interventions for Improving Lung Function and Controlling Inflammation.Pharmaceutical research · 2026Review
- Rhamnolipid-augmented medium enhances growth ofApplied and environmental microbiology · 2026Article
- Dirhamnolipids fromACS omega · 2026Article
- Biosurfactants as Antibiofilm Agents for Medical Devices: Mechanisms, Evidence and Integration into Infection Prevention and Control.Microorganisms · 2026Review
- Genome-mining revealed biosurfactant production capacity and gene co-occurrence patterns in diverse ecosystems.Microbial cell factories · 2026Article
- Biosurfactants in Food: Advances, Innovative Applications and Functional Perspectives.Foods (Basel, Switzerland) · 2026Review
- Beyond antibiotics: the expanding horizon of microbial natural products.Frontiers in antibiotics · 2026Review
- Attenuated Strains of Pseudomonas aeruginosa: A Promising Cell Factory for Rhamnolipid Production.Microbial biotechnology · 2025Review
- Sugar Esters of Fatty Acids: Chemo-Enzymatic Synthesis and Biological Activity.Molecules (Basel, Switzerland) · 2025Review
- Liposome-encapsulated antibiotics and biosurfactants: an effective strategy to boost biofilm eradication in cooling towers.Microbial cell factories · 2025Article
- Combinatorial discovery of microtopographical landscapes that resist biofilm formation through quorum sensing mediated autolubrication.Nature communications · 2025Article
- Optimizing Rhamnolipid Performance by Modulating the Expression of Fatty Acid Synthesis GenesGenes · 2025Article
- Rhamnolipid-Modified PHB-Ectoine Nanoparticles for Multifunctional Skin Protection Against UVB, Irritation, and Bacteria.ACS omega · 2025Article
- Investigating the wettability of neem oil nanoemulsion as a green pesticide on leaf surfaces - optimizing formulation, assessing stability, and enhancing wettability.RSC advances · 2025Article
- Genetically engineeredFrontiers in microbiology · 2025Article
- Trends in immune cell profiles of osteomyelitis: a clinical study supported by Mendelian randomization analysis.Frontiers in medicine · 2025Article
- Exploration of novel bioactive compounds from the microbiome of fish and shellfish as an alternative to replace antibiotic drugs in aquaculture farming.Gut microbiome (Cambridge, England) · 2025Review
- A Comprehensive Review on Bioactive Molecules and Advanced Microorganism Management Technologies.Current issues in molecular biology · 2024Review
- The pH and Sucrose Influence Rhamnolipid Action Toward Planktonic and Biofilms ofMicroorganisms · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhamnolipids (RLs) are surface-active compounds and belong to the class of glycolipid biosurfactants, mainly produced from Pseudomonas aeruginosa. Due to their non-toxicity, high biodegradability, low surface tension and minimum inhibitory concentration values, they have gained attention in various sectors like food, healthcare, pharmaceutical and petrochemicals. The ecofriendly biological properties of rhamnolipids make them potent materials to be used in therapeutic applications. RLs are also known to induce apoptosis and thus, able to inhibit proliferation of cancer cells. RLs can also act as immunomodulators to regulate the humoral and cellular immune systems. Regarding their antimicrobial property, they lower the surface hydrophobicity, destruct the cytoplasmic membrane and lower the critical micelle concentration to kill the bacterial cells either alone or in combination with nisin possibly due to their role in modulating outer membrane protein. RLs are also involved in the synthesis of nanoparticles for in vivo drug delivery. In relation to economic benefits, the post-harvest decay of food can be decreased by RLs because they prevent the mycelium growth, spore germination of fungi and inhibit the emergence of biofilm formation on food. The present review focuses on the potential uses of RLs in cosmetic, pharmaceutical, food and health-care industries as the potent therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.